Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Pharmacyclics, Inc. (NasdaqNM:PCYC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 23Earnings Announcement
Aug 22Price hit new 52-week low ($17.50)
Location
995 E. Arques Avenue
Sunnyvale, CA 94086
Phone: (408) 774-0330
Fax: (408) 774-0340
Email: info@pcyc.com
Employees (last reported count): 146
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 30%
·Institutional: 77% (110% of float)
(182 institutions)
·Net Inst. Selling: 40.0K shares
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Pharmacyclics Inc. is a pharmaceutical company developing products to improve upon current therapeutic approaches to the treatment of cancer, atherosclerosis and retinal disease. The Company uses its expertise in the chemistry of biologically-active metal-containing compounds to develop patented molecules called texaphyrins which, when injected, accumulate in tumor growths, in the diseased portions of major blood vessels and in small blood vessel growths in the retina. Its lead texaphyrin-based product candidates are: XCYTRIN, a molecule to enhance the effects of radiation and chemotherapy in treating cancer; LUTRIN, a molecule for use in photodynamic therapy of cancer; ANTRIN, a molecule to treat atherosclerosis via photoangioplasty; and OPTRIN, a molecule to treat age-related macular degeneration, a disease of the retina caused by growth of small blood vessels, which can lead to blindness.
More from Market Guide: Expanded Business Description

Financial Summary
Pharmacyclics Inc., develops pharmaceutical products to improve upon therapeutic approaches to the treatment of cancer, atherosclerosis and retinal disease. For the nine months ended 3/31/01, revenues fell 71% to $409 thousand. Net loss rose 39% to $22.7 million. Revenues reflect a decrease in contract revenues associated with the development of LUTRIN. Higher loss was partially offset by reduced drug purchase costs.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 2,712; after tax earnings were -8,194. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Richard Miller, M.D., 49
Pres, CEO
$300K
Leiv Lea, 46
CFO, VP of Fin. and Admin.
181K
Cynthia Ladd, 45
Sr. VP, Sec., Gen. Counsel
--  
Marc Steuer, 53
Sr. VP of Bus. Devel.
262K
Hugo Madden, Ph.D., 50
VP of Chemical Operations
174K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PCYCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Aug-2001
$17.50 
Recent Price$20.11 
52-Week High
on 8-Nov-2000
$60.00 
Beta1.26 
Daily Volume (3-month avg)134.9K
Daily Volume (10-day avg)231.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-61.3%
52-Week Change
relative to S&P500
-48.1%
Share-Related Items
Market Capitalization$323.9M
Shares Outstanding16.1M
Float11.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$10.07 
Earnings (ttm)-$1.93 
Earnings (mrq)-$0.51 
Sales (ttm)$0.19 
Cash (mrq*)$8.38 
Valuation Ratios
Price/Book (mrq*)2.00 
Price/EarningsN/A 
Price/Sales (ttm)103.50 
Income Statements
Sales (ttm)$3.12M
EBITDA (ttm*)-$39.6M
Income available to common (ttm)-$30.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-17.51%
Return on Equity (ttm)-18.04%
Financial Strength
Current Ratio (mrq*)31.82 
Debt/Equity (mrq*)0 
Total Cash (mrq)$152.8M
Short Interest
As of 8-Aug-2001
Shares Short1.87M
Percent of Float16.6%
Shares Short
(Prior Month)
1.47M
Short Ratio13.11 
Daily Volume143.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.